Healthcare Realty Trust Inc (HR) 28.11 $HR 3 Buy-Rated

New Post Public Reply Private Reply Replies (0) Message Board

Mar 22, 2015 at 2:25 AM

Healthcare Realty Trust Inc (HR) 28.11 $HR

3 Buy-Rated Dividend Stocks Taking The Lead: WES, HR, ETR
at The Street - Wed Mar 18, 10:31AM CDT
These 3 dividend stocks are rated a Buy by TheStreet
ETR: 79.05 (+1.11), HR: 28.11 (+0.90), WES: 64.94 (+0.14)

Health Care REIT Showdown: March Madness Continues
Brad Thomas - at Seeking Alpha - Mon Mar 16, 5:45AM CDT

MPW: 15.22 (+0.56), BMR: 23.24 (+0.85), HCP: 42.44 (+1.20), ARE: 102.42 (+2.94), HCN: 79.13 (+2.35), UHT: 55.48 (+1.32), HR: 28.11 (+0.90), DOC: 17.76 (+0.65), O: 53.65 (+1.41), VTR: 73.73 (+1.87), SNH: 22.98 (+0.70), CTRE: 13.61 (+0.40), OHI: 40.67 (+0.75), NHI: 72.61 (+1.74), LTC: 45.46 (+0.88), HTA: 29.02 (+1.08)

Health Care REITs Equities Technical Briefing -- HCP Inc., Ventas, Health Care REIT, Sabra Health Care REIT, and Healthcare Realty Trust
PR Newswire - Fri Mar 13, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
HCP: 42.44 (+1.20), HCN: 79.13 (+2.35), SBRA: 34.02 (+0.79), HR: 28.11 (+0.90), VTR: 73.73 (+1.87)

3 Buy-Rated Dividend Stocks: HR, CLDT, FE
at The Street - Thu Mar 05, 9:30AM CST
These 3 dividend stocks are rated a Buy by TheStreet
CLDT: 30.85 (+0.88), FE: 36.38 (+0.44), HR: 28.11 (+0.90)

Health Care REIT (HCN) Unveils $1.5B Public Offering - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 3:37PM CST
Health Care REIT(HCN) has announced a public offering of nearly 19.6 million shares at a price of $75.50 per share for $1.5 billion.
MPW: 15.22 (+0.56), HCN: 79.13 (+2.35), HR: 28.11 (+0.90), VTR: 73.73 (+1.87)

Insider Trading Alert - WD, ANIK And HR Traded By Insiders
at The Street - Tue Mar 03, 9:30AM CST
Stocks with insider trader activity include WD, ANIK and HR
WD: 17.68 (+0.18), HR: 28.11 (+0.90), ANIK: 40.84 (-0.63)

Can HCN Ride High on Investments of $2.2B in Q1 2015? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 1:30PM CST
Health Care REIT Inc. (HCN) currently expects to close around $2.2 billion of investments in the first quarter of 2015.
MPW: 15.22 (+0.56), HCN: 79.13 (+2.35), HR: 28.11 (+0.90), PSA: 199.12 (+4.88)

Health Care REIT Q4 FFO & Revenues Beat, Guides In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 20, 10:57AM CST
Health Care REIT (HCN) reported fourth-quarter 2014 normalized FFO of $1.03 per share, a penny ahead of the Zacks Consensus Estimate and up 4 cents year over year.
MPW: 15.22 (+0.56), HCN: 79.13 (+2.35), HR: 28.11 (+0.90), PSA: 199.12 (+4.88)

Healthcare Realty Trust Incorporated's (HR) CEO David Emery on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 18, 1:47PM CST

HR: 28.11 (+0.90)

Healthcare Realty Q4 FFO In Line with Estimates, Rises Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 9:09AM CST
Healthcare Realty Trust (HR) reported fourth-quarter 2014 normalized FFO of 38 cents per share, in line with the Zacks Consensus Estimate and 2 cents up year over year.
HST: 21.72 (+0.49), HR: 28.11 (+0.90), PSA: 199.12 (+4.88), PLD: 44.39 (+0.71)

Healthcare Realty FFO in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 4:10PM CST

HR: 28.11 (+0.90)

Healthcare Realty Trust Reports Normalized FFO Of $0.38 Per Share For The Fourth Quarter
PR Newswire - Tue Feb 17, 4:05PM CST
Healthcare Realty Trust Incorporated (NYSE: HR) today announced results for the fourth quarter ended December 31, 2014. Normalized FFO for the three months ended December 31, 2014 totaled $0.38 per diluted common share. Over the same time period, year-over-year revenue grew by $6.4 million to $95.0 million. The Company reported net income attributable to common stockholders for the quarter of $18.1 million.
HR: 28.11 (+0.90)

Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 16, 4:35PM CST

PEI: 23.75 (+0.80), ANAD: 1.08 (+0.05), VECO: 32.71 (+0.42), A: 42.21 (unch), ZIXI: 4.06 (-0.04), HR: 28.11 (+0.90), O: 53.65 (+1.41), NP: 62.49 (+1.25), CHE: 122.12 (+1.77), JACK: 97.07 (+0.42), PLAB: 8.63 (+0.13), ENPH: 12.48 (-0.39), VNO: 113.44 (+4.39), FOSL: 83.20 (+0.67), VRNS: 29.92 (+0.19), PEB: 49.15 (+2.21), ROG: 83.28 (+0.29), EXAC: 25.30 (+0.52), TEX: 26.71 (+0.55), PBPB: 13.10 (+0.14), UCTT: 7.80 (-0.68), HTA: 29.02 (+1.08), DVN: 58.66 (+0.40), RAX: 53.63 (-0.27), MASI: 31.01 (-0.55), FE: 36.38 (+0.44), XEC: 110.62 (+3.39), RAIL: 30.14 (+0.35), HTS: 18.71 (+0.30), CLD: 6.39 (+0.15), LZB: 27.04 (+0.75), WTS: 55.53 (+0.59), EQY: 27.49 (+0.44), KALU: 76.66 (+0.05), CF: 290.23 (+0.20), KAR: 37.57 (+0.38), VMI: 122.00 (-1.43), OHI: 40.67 (+0.75), NCLH: 53.69 (+0.08), ADI: 61.07 (+1.07), FLS: 57.60 (+0.32), FANG: 72.34 (+0.85), AMC: 35.68 (+0.23), PHH: 24.03 (+0.37), OMI: 34.20 (+0.03), IPHS: 57.62 (+1.45)

Ventas (VTR) Beats Q4 FFO on Strong Revenues, Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 10:39AM CST
Ventas' (VTR) fourth-quarter 2014 normalized funds from operations of $1.15 per share came in 2 cents higher than the Zacks Consensus Estimate of $1.13 per share.
HCN: 79.13 (+2.35), HR: 28.11 (+0.90), AHT: 10.16 (+0.27), VTR: 73.73 (+1.87)

Buy These Top 3 Buy-Rated Dividend Stocks Today: HR, BCE, BMR
at The Street - Wed Feb 11, 9:38AM CST
These 3 dividend stocks are rated a Buy by TheStreet
BMR: 23.24 (+0.85), BCE: 42.17 (+0.12), HR: 28.11 (+0.90)

HCP Q4 FFO Beats Estimates, Up Y/Y, Guides In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 10:13AM CST
HCP Inc. (HCP) reported fourth-quarter 2014 adjusted FFO per share of 79 cents, 2 cents ahead of the Zacks Consensus Estimate. Results benefited from solid growth in top line.
MPW: 15.22 (+0.56), HCP: 42.44 (+1.20), HR: 28.11 (+0.90), VTR: 73.73 (+1.87)

Healthcare Realty Trust Up 18.3% Since SmarTrend Uptrend Call (HR)
Comtex SmarTrend(R) - Fri Feb 06, 9:49AM CST
SmarTrend identified an Uptrend for Healthcare Realty Trust (NYSE:HR) on October 14th, 2014 at $25.18. In approximately 4 months, Healthcare Realty Trust has returned 18.35% as of today's recent price of $29.80.
HR: 28.11 (+0.90)

Healthcare Realty Trust to pay Q4 dividend of USD0.30 per share
M2 - Wed Feb 04, 5:26AM CST
Healthcare trust Healthcare Realty Trust (NYSE:HR) declared on Tuesday a dividend of USD0.30 per share of its common stock for the quarter ended 31 December 2014.
HR: 28.11 (+0.90)

Healthcare Realty Trust declares dividend of USD0.30 per share for quarter
M2 - Wed Feb 04, 5:22AM CST
Real estate investment trust Healthcare Realty Trust Incorporated (NYSE:HR) disclosed on Tuesday that it will pay a common stock cash dividend of USD0.30 per share for the quarter ended 31 December 2014.
HR: 28.11 (+0.90)

Healthcare Realty declares $0.30 dividend
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 1:54PM CST

HR: 28.11 (+0.90)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Historic Records Set at 2026 CNO Monumental Marathon

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Boston STEM Expo Sparks Young Minds in Engineering

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...